Life Sciences & Medicine Active Updated Aug 1, 2026
A cochlear implant for vision
Science Corporation's retinal implant restores enough central vision for people who lost it to age-related macular degeneration to read books and recognize road signs again. The arc will run as the device, just cleared for commercial sale in Europe, moves toward a possible US launch and wider real-world use.
The story so far
-
Aug 1, 2026 Latest
SingularityHub reported that Science Corporation's PRIMA implant, a chip smaller than a grain of rice paired with camera-mounted glasses, produced an average gain of 25.5 letters, more than five lines, on a standard eye chart across a 38-patient trial in five countries, and the company said the first commercial implants are expected in Germany within weeks.
-
Jul 26, 2026
Following its EU approval, Science Corporation shared early patient outcomes for the Prima implant: a French patient finished a 300-page novel and mailed it to the company, another sketched the Sydney Opera House, and patients have played crossword puzzles and Sudoku. CEO Max Hodak said current vision is like looking through a straw, with full color and native sharpness as the device's next target.
-
Jul 23, 2026
Science Corporation announced European regulatory approval for commercial sale of its retinal implant, which restores enough central vision for age-related macular degeneration patients to read books and make out road signs again. Founder Max Hodak called it a cochlear implant for vision, and the company expects a US launch as soon as 2027.
This story moves with the morning letter.
When this arc advances, the timeline above grows the same morning. One short, warm letter with the day's real progress in science, medicine and beyond. Free, every day.
Free forever, no spam. One click to unsubscribe, and we never sell your email.